Sign inJoin waitlistJoin the waitlist

John Suh

Former Residency Program Director for Department of Radiation Oncology · Cleveland Clinic Outpatient Center A - Austintown

Credentials: · · ·

History

Former Residency for Department of Radiation Oncology Residency · Cleveland Clinic Outpatient Center A - Austintown
Present
Cleveland Clinic Foundation
Present
Department of Radiation Oncology · Cleveland Clinic Outpatient Center A - Austintown
Present

Cleveland Clinic
1994–1995
Radiation Oncology
1991–1995
Preliminary or Transitional Year
1990–1991
Univ of Miami Leonard M. Miller Sch of Med
1986–1990
University of Miami
1982–1986

Research

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases
Journal of Clinical Oncology · 2012 · 1,150 citations
Response assessment criteria for brain metastases: proposal from the RANO group
Review · The Lancet Oncology · 2015 · 916 citations
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
New England Journal of Medicine · 2016 · 795 citations

Samuel Chao
157 papers · 5 as a resident
Gene Barnett
130 papers
MV
Michael Vogelbaum
83 papers
Lilyana Angelov
82 papers
Erin Murphy
70 papers · 5 as a fellow
RK
Rupesh Kotecha
47 papers · 18 as a resident
Alireza Mohammadi
44 papers
Manmeet Ahluwalia
44 papers · 3 as a fellow
David Peereboom
37 papers
Glen Stevens
37 papers
Minesh Mehta
31 papers
RW
Robert Weil
28 papers

Clinical trials

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Principal investigator · Completed
Case Comprehensive Cancer Center
2005–2012
Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer
Study chair · Completed · Phase 3
Spectrum Pharmaceuticals, Inc
2004–2007
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Site PI · Recruiting · Phase 3
NRG Oncology
2017–2032